Literature DB >> 9734673

Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis.

K Gaffney1, D G Scott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9734673     DOI： 10.1093/rheumatology/37.8.824

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN： 0263-7103


× No keyword cloud information.
  7 in total

Review 1.  Genetic markers of treatment response in rheumatoid arthritis.

Authors:  Joanna Wesoly; Judith A M Wessels; Henk-Jan Guchelaar; Tom W J Huizinga
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

2.  Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis.

Authors:  Maria Angélica Raffaini Covas Pereira da Silva; Ciomar Aparecida Bersani-Amado; Emy Luiza Ishii-Iwamoto; Lívia Bracht; Silvana Martins Caparroz-Assef
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

3.  Reactivation of Darier's disease following Azathioprine treatment for thyroid eye disease.

Authors:  S L Levy; S M Salvi
Journal:  Eye (Lond)       Date:  2013-02-01       Impact factor: 3.775

Review 4.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

5.  Immune effector cells produce lethal DNA damage in cells treated with a thiopurine.

Authors:  Ilse Daehn; Peter Karran
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

6.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 7.  Adverse Events in NMOSD Therapy.

Authors:  Katrin Giglhuber; Achim Berthele
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.